- 中文名称
Relatlimab 生物类似药, 人 LAG-3 单克隆抗体
- 英文名字
- Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody
- 供应商
- Promab
- 产品货号
- PMB-B00051
- 产品报价
- ￥询价/1mg/5mg/20mg
- 产品说明书
- 点击查看
- 购买方式
- 90%产品中国有现货库存。银行转账、电汇、支票、现金，在线支付宝及网银支付，或直接与我们电话联系400-6800-868
- 产品新闻
- 背景资料
- What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3–blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer.nnRelatlimab and the anti–PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti–PD-1 monotherapy.
- 应用类型
- Flow cytometry, animal model study
- 免疫原
- Human LAG-3
- 来源宿主
- CHO cells
- 反应性
- Human
- 保存建议
- Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
- 其他
- Lymphocyte Activation Gene 3, LAG3, CD223, Cluster of Differentiation 223
- 注意
-
该页面的中文产品信息的翻译，仅供参考。准确的产品信息请以厂家的英文说明书为准。下单前，请浏览说明书确认。
-
